CNIPA.AI

Company patentsInnovative medicines and biopharmaceuticals

COMPANY PATENT INTELLIGENCE

Hengrui Pharma Patent Portfolio Analysis

Explore medicines, formulations and related technologies through publications attributed to selected Hengrui Pharma legal entities.

Partial name or date coverage · counts are lower boundsData as of 2026-11-17Data scope
Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Source search matches
618
Published 2025-01-01 — 2025-12-31 · Source Google Patents
Applicant names included in these statistics
JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD · JIANGSU HENGRUI PHARMACEUTICALS CO LTD
Publication dates collected
Not recorded in this snapshot
Reviewed names not covered
JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. · 江苏恒瑞医药股份有限公司
Compare with other companies
Collected patent publications

≥618docs

52 per month · peak 2025-03 (82)

Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.

01Key figures

Applications
601
By application number; publication and grant count once
Invention
396
66% of applications
Utility model
0
0% of applications
Patent families
320
By the source family ID
Green technology
—
The source has no CPC codes
Concentration
1.23HHI
Sum of squared field shares; higher is more concentrated

INSIGHT 01Fact

93%

93% of applications are in Pharmaceuticals

556 applications in this field, 539 of them in IPC A61K — the main axis of the portfolio.

Method: Field applications ÷ applications with IPC

02Technology landscape

598 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.

  • Instruments
  • Chemistry
Explore reviewed themes, sample patents and evidence

03Rhythm

Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.

This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.

Cells count publications only within the collected names and dates. Missing periods are not shown; the company portfolio is incomplete.
Technology field25-0125-0225-0325-0425-0525-0625-0725-0825-0925-1025-1125-12
Pharmaceuticals303776495647514147464844
Organic fine chemistry141944283226331823222523
Biotechnology151924211410181120211918
Analysis of biological materials111320200011
Measurement010000110000
Macromolecular chemistry, polymers000000000201
Chemical engineering001010000000

Filing years of the collected applications

Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.

  • 20145
  • 20152
  • 201610
  • 20179
  • 201815
  • 201918
  • 202025
  • 202138
  • 202261
  • 2023142
  • 2024165
  • 2025111Publication lag may still apply

Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.

Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.

04Strategy profile

Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.

Concentration

1.23
0.001.43

Position 2 of 26 published companies.

Method: Sum of squared field shares

Utility model share

0%
0%33%

Position 9 of 26 published companies.

Method: Utility model documents ÷ all documents

Green technology share

—

The source has no CPC codes, so this cannot be computed.

Method: Documents with CPC Y02 ÷ documents with CPC

Manufacturing and inspection share

0.8%
0%50%

Position 21 of 26 published companies.

Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications

05Collaboration

Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.

Shanghai hengrui pharmaceutical co ltd322Other co-applicant · relationship unverified
SHANGHAI SHENGDI PHARMACEUTICAL CO LTD109Other co-applicant · relationship unverified
SHANGHAI SENHUI MEDICINE CO LTD45Other co-applicant · relationship unverified
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD29Other co-applicant · relationship unverified
SHANGHAI SENHUI PHARMACEUTICAL CO LTD17Other co-applicant · relationship unverified
FUJIAN SHENGDI PHARMACEUTICAL CO LTD8Other co-applicant · relationship unverified
SUZHOU SHENGDIYA BIOLOGICAL MEDICINE CO LTD8Other co-applicant · relationship unverified
SHANDONG SUNCADIA MEDICINE CO LTD7Other co-applicant · relationship unverified
TIANJIN HENGRUI MEDICINE CO LTD4Other co-applicant · relationship unverified
SHANGHAI FOURTH PEOPLES HOSPITAL3Other co-applicant · relationship unverified

Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.

Review the entity list

06Entities and scope

Entity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.

Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.

Showing 1 of 1 entities

江苏恒瑞医药股份有限公司

Primary entityVerifiedSome names covered
Names collected in this snapshot
JIANGSU HENGRUI PHARMACEUTICALS CO LTD · JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD
Names outside this snapshot
江苏恒瑞医药股份有限公司 · Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Recorded relationship dates
Not recorded — Not recorded

上交所披露中英文法人名;候选标准名的原始申请人示例对应同一法人。只纳入本体,联合申请中的其他法人不自动扩展到其独立文献。

Review evidence

Relationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.

07Observations

Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.

Technology themes and evidence

Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.

Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.

Showing 2 sample patents · 0 linked observations

Reading samples

Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.

US20250011411A1

Anti-SOST Antibody Pharmaceutical Composition and Use Thereof

The abstract combines an anti-SOST antibody with an antioxidant. Claim 1 further identifies the antibody through specified heavy- and light-chain CDR sequences and alternatives. The reading therefore concerns both antibody identity and formulation components, rather than every anti-SOST medicine.

Bibliography and claim evidence
Applicants
Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Shanghai Hengrui Pharmaceutical Co., Ltd.
Application date
2022-11-30
Publication date
2025-01-09
English summary of cited claim evidence
US20250011411A1, claim 1 (reading note, not a verbatim quotation)The abstract combines an anti-SOST antibody with an antioxidant. Claim 1 further identifies the antibody through specified heavy- and light-chain CDR sequences and alternatives. The reading therefore concerns both antibody identity and formulation components, rather than every anti-SOST medicine.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

US20250043022A1

Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof

The abstract describes a molecule binding both PSMA and CD3. Claim 1 requires at least one binding moiety for each target and specifies variable-region and CDR sequence alternatives. This supports a reading of dual-target molecular design; target names alone do not establish claim coverage or clinical performance.

Bibliography and claim evidence
Applicants
Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Shanghai Hengrui Pharmaceutical Co., Ltd.
Application date
2023-02-07
Publication date
2025-02-06
English summary of cited claim evidence
US20250043022A1, claim 1 (reading note, not a verbatim quotation)The abstract describes a molecule binding both PSMA and CD3. Claim 1 requires at least one binding moiety for each target and specifies variable-region and CDR sequence alternatives. This supports a reading of dual-target molecular design; target names alone do not establish claim coverage or clinical performance.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

08Publication jurisdictions

22 publication offices · 618 documents

Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.

  1. CNChina149
  2. EPEuropean Patent Office publication89
  3. WOPCT international publication72
  4. TWTaiwan66
  5. MXMexico62
  6. USUnited States58
  7. KRSouth Korea41
  8. AUAustralia33
Show 14 more jurisdictions
  1. CACanada16
  2. MYMalaysia9
  3. JPJapan4
  4. ILIsrael3
  5. CLChile2
  6. COColombia2
  7. ESSpain2
  8. PEPeru2
  9. PLPoland2
  10. ZASouth Africa2
  11. CRCosta Rica1
  12. DODominican Republic1
  13. MAMorocco1
  14. UAUkraine1

09Documents

307 published documentsClear filtersNewest first
  1. EP4596538A4

    Invention publication

    Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method

    JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-31
  2. CN121202895A

    Invention publication

    Polycyclic compound, preparation method thereof and application thereof in medicine

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-26
  3. CN121177509A

    Invention publication

    Antibody-drug conjugate and medical application thereof

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryBiotechnologyPharmaceuticals

    2025-12-23
  4. Fused bicyclic derivatives, preparation method and medical use thereof

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-21
  5. CN121159575A

    Invention publication

    Amino-substituted heteroaromatic ring compound, preparation method and medical application thereof

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-19
  6. CN121175296A

    Invention publication

    Preparation method of formamide compound

    SHANGHAI SENHUI PHARMACEUTICAL CO LTD / SHANGHAI SHENGDI PHARMACEUTICAL CO LTD / JIANGSU HENGRUI MEDICINE CO

    Organic fine chemistry

    2025-12-19
  7. CN121175309A

    Invention publication

    Amorphous forms, crystals, preparation methods and uses of dioxopiperidine compounds or pharmaceutically acceptable salts thereof

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-19
  8. US2025382287A1

    Invention publication

    Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same

    JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-18
  9. WO2025256544A1

    Invention publication

    Preparation method for 1-aminoalkyl-modified ribofuranose derivative

    FUJIAN SHENGDI PHARMACEUTICAL CO LTD / JIANGSU HENGRUI PHARMACEUTICALS CO LTD

    Organic fine chemistry

    2025-12-18
  10. EP4578852A4

    Invention publication

    Heterocyclic compound, method for preparing same, and pharmaceutical use thereof

    JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-17
  11. EP4663635A1

    Invention publication

    Crystalline form of sulfonamide derivative and preparation method therefor

    JIANGSU HENGRUI PHARMACEUTICALS CO LTD / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-17
  12. CN121135745A

    Invention publication

    Pyrimidine derivatives, preparation method thereof and application thereof in medicine

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-16
  13. KR20250174948A

    Invention publication

    질소 함유 테트라시클릭 화합물의 결정 형태 및 이의 제조 방법

    JIANGSU HENGRUI PHARMACEUTICALS CO LTD / SHANDONG SUNCADIA MEDICINE CO LTD

    Organic fine chemistryPharmaceuticals

    2025-12-15
  14. KR20250174969A

    Invention publication

    올리고뉴클레오티드 유사체 또는 이의 염을 제조하기 위한 중간체 및 이의 제조 방법

    SHANGHAI SENHUI MEDICINE CO LTD / JIANGSU HENGRUI PHARMACEUTICALS CO LTD

    Organic fine chemistry

    2025-12-15
  15. CN121108138A

    Invention publication

    Pyrimidine derivative, preparation method thereof and application thereof in medicine

    JIANGSU HENGRUI MEDICINE CO / Shanghai hengrui pharmaceutical co ltd

    Organic fine chemistryPharmaceuticals

    2025-12-12
  16. Application of jak inhibitors in kidney disease

    JIANGSU HENGRUI MEDICINE CO

    Organic fine chemistryPharmaceuticals

    2025-12-11
  17. US12492166B2

    Invention grant

    Sulfonylurea derivative and medical uses thereof

    SHANGHAI SENHUI MEDICINE CO LTD / SHANGHAI SHENGDI PHARMACEUTICAL CO LTD / JIANGSU HENGRUI PHARMACEUTICALS CO LTD

    Organic fine chemistryPharmaceuticals

    2025-12-09
  18. CN121064220A

    Invention publication

    SMTP-7 derivative and application thereof

    FUJIAN SHENGDI PHARMACEUTICAL CO LTD / SHANGHAI SENHUI PHARMACEUTICAL CO LTD / SHANGHAI SHENGDI PHARMACEUTICAL CO LTD / JIANGSU HENGRUI MEDICINE CO

    Organic fine chemistryPharmaceuticals

    2025-12-05
  19. CN121064221A

    Invention publication

    SMTP-7 derivative and application thereof

    FUJIAN SHENGDI PHARMACEUTICAL CO LTD / SHANGHAI SENHUI PHARMACEUTICAL CO LTD / SHANGHAI SHENGDI PHARMACEUTICAL CO LTD / JIANGSU HENGRUI MEDICINE CO

    Organic fine chemistryPharmaceuticals

    2025-12-05
  20. WO2025247268A1

    Invention publication

    Method of preparing boric acid derivative serving as beta-lactamase inhibitor

    JIANGSU HENGRUI PHARMACEUTICALS CO LTD / SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD

    Organic fine chemistry

    2025-12-04

Titles come from the source bibliography. Select a number to read the full document on this site.

Drafting a patent in this field?

Upload your invention disclosure and get an editable draft that follows CNIPA practice.

Start drafting

10Method and sources

Counting units

Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.

Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.

Entity scope

These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.

Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Applicant names included in these statistics
JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD · JIANGSU HENGRUI PHARMACEUTICALS CO LTD
Reviewed names not covered
JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. · 江苏恒瑞医药股份有限公司
Current entity configuration and review evidence

The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.

江苏恒瑞医药股份有限公司

Configured aliases: Jiangsu Hengrui Pharmaceuticals Co., Ltd. · JIANGSU HENGRUI PHARMACEUTICALS CO LTD · JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD

Original review note: 上交所披露中英文法人名;候选标准名的原始申请人示例对应同一法人。只纳入本体,联合申请中的其他法人不自动扩展到其独立文献。

Review evidence

Data sources

  • Google Patents · PartialPublished 2025-01-01 to 2025-12-31 · retrieved 2026-11-17 · 618 included · 0 out of scopeSource and terms

Found a wrong attribution or number? Tell us